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Abstract 
Triple-negative breast cancers (TNBC) are the most aggressive subtype of breast cancer 
with few treatment options and poor outcomes. TNBCs are characterized by elevations in 
hexosamine biosynthetic pathway (HBP) enzyme expression, hyaluronan synthase 2 (HAS2) 
expression and hyaluronan (HA) production. Glutamine is an important substrate for HA 
production via the HBP. 6-diazo-5-oxo-L-norleucine (DON) is a well-known glutamine 
antagonist with validated antitumoral efficacy. This project examined the effects of DON on HA 
production and energy metabolism in TNBC cells. We examined the effect of DON treatment on 
Hs578T cells, which represent the mesenchymal stem-like subtype of TNBC. We specifically 
analyzed the effects of DON on Hs578T cell variants segregated into high (HAHigh) and low 
(HALow) HA producing subpopulations. DON decreased cell proliferation in both cell lines with 
HALow cells showing a more pronounced effect with almost 40% decrease in cell number after 
treatment with 2.5μM DON for 72 hours. DON reduced cell-associated HA in a dose dependent 
manner in HAHigh cells whereas HALow cells exhibited no effect. Seahorse extracellular flux 
analysis indicated that HAHigh cells were more sensitive to DON with about 60% decrease in 
glycolysis compared to an almost 40% decrease in HALow cells. The observed changes in 
glycolysis and reduction in HA production in HAHigh cells support the findings that DON can 
inhibit glutamine dependent enzymes in HBP and hinder tumor growth in TNBC cells. 
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Introduction 
 Healthy breast epithelial cells receive messages from hormones (estrogen and 
progesterone) to maintain functions and proliferate as needed (ie, during puberty or pregnancy). 
Cell growth is also regulated by HER2, a growth factor receptor often up-regulated in breast 
cancers. High activity of HER2 or the receptors for estrogen and progesterone drive breast 
cancer growth and thus represent therapeutic drug targets. Therapies targeting the effects of these 
hormones and HER2 effectively slow and even stop the growth of breast cancers that express 
these proteins. Triple-negative breast cancer (TNBC) refers to breast cancers that do not express 
the estrogen receptor (ER), progesterone receptor (PR) or HER2 (Foulkes et al., 2010). Triple-
negative tumors comprise 15-20% of breast cancers, mostly women with mutations in the 
BRCA1 gene (Perou, 2011).  Since hormones or HER2 do not fuel their growth, TNBCs are 
more difficult to treat and often require combination therapies. Although some data suggest that 
chemotherapies have better effects on TNBC than other types of breast cancer, overall, prognosis 
for these patients remains poor (De Giorgi et al., 2007). As a result, TNBC has a more aggressive 
metastatic nature, and shorter adjuvant and neoadjuvant disease-free period. 
 Many tumors alter critical biochemical pathways to enhance nutrient supply for rapid 
growth. These changes can affect cellular metabolism and induce cellular stress (Wellen et al., 
2010). During normal cell growth, glucose and glutamine are the primary substrates for energy 
and biosynthesis of macromolecules for cell proliferation. Cancer cells often undergo a 
“metabolic switch” from mitochondrial respiration to glycolysis even when oxygen is available 
(Warburg et al., 1927). The hexosamine biosynthetic pathway (HBP, Figure 1) is another key 
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regulator of tumor promotion as it metabolizes glucose and glutamine to hexoses that can be 
incorporated into hyaluronic acid (HA), a glycan associated with aggressive tumors. 
 
Figure 1. Effects of DON on hexosamine biosynthetic pathway (HBP) in pancreatic tumors (Sharma et al., 2019). The cell 
takes in glucose, processes it through a two-step conversion to fructose-6P. After that, 95% of fructose-6p goes to glycolysis and 
around 5% goes through glucosamine-6P conversion by GFAT (glutamine: fructose-6-phosphate amidotransferase) with the aid 
of glutamine that cell took in. GFAT is the rate-limiting enzyme for the formation of hexosamine products and acts as a key 
regulator of HBP. GNA1/GNPNAT1 helps convert glucosamine-6P into GlcNAc-6P using acetyl-CoA from fatty acid 
metabolism. PGM3/AGM1 then catalyze the conversion to GlcNAc-1P. UDP-GlcNAc is synthesized by UAP/AGX1 using UTP 
from the nucleotide metabolism pathway. N-linked and O-linked glycosylation in ER and Golgi occurred for O-GlcNAc 
modification of nuclear and cytoplasmic proteins 
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The end products of the HBP, UDP-N-aceytylglucosamine (UDP-GlcNAc) and UDP-
glucuronic acid (UDP-GlcUA) are essential substrates for HA synthesis (Vigetti et al., 2012). 
Analyses of breast cancer mouse models indicated HBP enzyme expression in carcinoma cells, 
with higher expression of Hyaluronan synthase 2 (HAS2) and higher HA production in 
aggressive breast cancer cells (Chokchaitaweesuk et al., 2019). As noted above, independent 
from the HBP, glutamine is also required for the production of glutamate (catalyzed by 
glutaminase and glutamine amidotransferase enzymes). Glutamate is thus important for HA 
synthesis, the mitochondrial tricarboxylic acid cycle (TCA cycle) and cellular energy production. 
6-diazo-5-oxo-L-norleucine (DON) is a glutamine antagonist with antitumoral efficacy as 
validated in various models (Yoshioka et al., 1992). DON can bind active sites of glutamine 
metabolic enzymes, such as GFAT in the HBP, and inhibit them by alkylation (Ortlund et al., 
2000). In vitro, DON treatment results in apoptosis through the disruption of mitochondria 
metabolism (Wu et al., 1999).  
This project studied the effects of DON on HA production and other relevant glutamine 
metabolic pathways in TNBC. Hs578T is an established human cell line that is representative of 
the mesenchymal stem-like subtype of TNBC. We hypothesized that DON treatment would have 
different effects on sub-populations of Hs578T cell lines that synthesize high or low amounts of 
HA. To test this hypothesis, parental Hs578T cells were sorted by flow cytometry into HAHigh 
and HALow populations. The HAHigh subclone demonstrated more aggressive properties, elevated 
HA production, and overexpression of enzymes that metabolize glucose and glutamine. We 
analyzed the impact of DON treatment on HAHigh and HALow cell growth with crystal violet 
assays and detected a pronounced effect at 2.5 µM DON treatment. Higher concentrations of 
DON with a shorter time point were utilized in the following experiments. Flow cytometry of 
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bHABP binding to cell-associated HA on subpopulations was performed after treatment with 5 
and 10 μM DON for 48 hours. We also characterized the effect of 24 hour treatment with 5 μM 
DON on metabolism (Mitochondrial Function and Glycolytic Function) of the subpopulations 
using the Agilent Seahorse XFp Analyzer.  
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Materials and Methods 
 
Cell Culture 
Hs578T cells, a triple-negative breast cancer (TNBC) cell line, was originally obtained 
from ATCC and was available in the Welsh lab. This “parental” cell line was sorted into High 
(HAHigh) and Low (HALow) HA populations by flow cytometry after incubation with biotinylated 
hyaluronic acid binding protein (bHABP) which binds to cell-associated HA. The resulting 
subclones were grown in Dulbecco's Modified Eagle Medium with high glucose (DMEM), 10% 
fetal bovine serum (FBS), 15nM HEPES and 10 µg/mL insulin. Cells were cultured every 4-5 
days at the density of 4,000 cells/cm2, with media replaced every 2 or 3 days, and kept in an 
incubator at 5% CO2 and 37°C. 
 
Cell Morphology - Confocal microscopy 
Lab-Tek II CC2 4-well chamber slides were used to plate Hs578T subclones with 5,000 
cells/cm2 for 72 h. 1% formaldehyde in PBS was used to fix cells for 15 minutes and PBS/1% 
BSA containing 0.02% sodium azide was used to block overnight. bHABP was diluted 1:30 in 
blocking buffer. The cells were incubated in the dilution for 30 minutes at room temperature in a 
humidified chamber. After the incubation period, the chamber slides were washed with PBS 3 
times. The slides were incubated with Alexa Fluor 488 streptavidin diluted 1:400 in blocking 
buffer. After three washes with PBS, coverslips were applied with Invitrogen Prolong Gold 
antifade mounting media containing DAPI to identify nuclei. Images were taken with a 40x oil 
immersion objective on a Leica DMI6000 microscope with TCS SP5 confocal laser scanner 
using Leica Application Suite AF version 2.6.0.7266 software. 
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Particle exclusion assay 
Lab-Tek II 4-well chambered coverglass #1.5 borosilicate was used to plate Hs578T 
subclones with 500 cells/cm2 density for 48h. The cells were rinsed with Sigma Hank’s Balanced 
salt solution, fixed for 10 min in 1% formaldehyde in HBSS at room temperature, washed three 
times with HBSS, and incubated for 15 min with Hoechst 33258 diluted 1:150 in PBS/0.2% BSA. 
The cells were washed three times with PBS/0.2% BSA, after which 7.5 x 108 fixed sheep red 
blood cells were overlaid onto cultures and allowed to settle for 20 min at 37°C. Images were taken 
with a 20x objective on the Leica DMI6000 confocal microscope. 
 
Crystal Violet Assay 
A simple method used to determine cell survival and growth is based on the use of crystal 
violet dye which binds to proteins and DNA, thus staining adherent cells in the culture 
(Feoktistova et al., 2016). This assay quantitatively assesses the density of cells which reflects 
both proliferation and cell death (apoptosis). Cells which lose the ability to attach to the substrate 
(including adherent cells triggered to undergo cell death) are not stained by the dye, decreasing 
the intensity of crystal violet staining. The crystal violet assay was applied to test the effect of 
DON on Hs578T HAHigh and HALow subclones. The subclones were plated on 24-well dishes at 
7,000 cells/ml density and treated with 0 µM, 0.5 µM, 1 µM, or 2.5 µM DON for 72 hours. After 
being fixed, washed, stained with crystal violet, and dried overnight, Triton X-100 was added to 
resuspend the dye. Plates were incubated for 30 minutes after which absorbance at 590nm was 
measured using a Victor microplate reader.  
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bHABP Flow Cytometry  
Hs578T subclones were plated in 100mm3 dishes (20,000 cells/mL) for one day. The 
subclones were incubated in respective treatments (5 µM DON, 10 µM DON) for 48 hours. The 
cells were trypsinized and pooled. Thereafter, all steps were performed at 4°C. The pooled cell 
suspension was blocked with PBS/4% BSA, incubated for 30 min with biotinylated HA binding 
protein (bHABP) diluted 1:30 in blocking buffer, and fluorescently labeled for 15 min with 
Alexa Fluor 488 streptavidin diluted 1:800 in blocking buffer. PBS/0.2% BSA was used for 
washes to remove unbound bHABP and streptavidin. Flow cytometry was performed on a BD 
LSR II Flow Cytometer and data was analyzed with FlowJo 7.6.5. 
 
Measuring Glycolytic Function  
Agilent Seahorse XFp Analyzer was used to measure glycolytic function in Hs578T 
HAHigh  and HALow cells after 24 h incubation in 5µM DON. Cells were plated in Seahorse 8-
well XFp cell culture microplates at 6,000 cells/well density in triplicate. For each replicate, 3 
wells were treated with 5µM DON and 3 wells were untreated. Cells were switched to buffer-
free XF assay media (Agilent Seahorse) containing 2mM glutamine one hour prior to assay. The 
Agilent Seahorse XFp Cell Glycolysis Stress Test measures key parameters of glycolytic 
function by directly measuring the extracellular acidification rate (ECAR). Seahorse XFp 
Analyzer measures ECAR in real-time of the 3 replicates through injections of glucose, 
Oligomycin, and 2-DG. After the plates were measured, cells in each well were sonicated. The 
data from the 3 replicates were normalized with the DNA concentration in each well, measured 
by NanoDrop™ 2000/2000c Spectrophotometers. 
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Measuring Mitochondrial Function  
The Agilent Seahorse XFp Analyzer was used to measure mitochondrial function in 
Hs578T HAHigh cells after 24 h incubation with 5µM DON. Cells were plated in Seahorse 8-well 
XFp cell culture microplates at 6,000 cells/well in triplicate. For each replicate, 3 wells were 
treated with 5µM DON and 3 wells were left untreated. Cells were switched to buffer-free XF 
assay media (Agilent Seahorse) containing 1 mM pyruvate, 25 mM glucose with 2mM glutamine 
one hour prior to assay. The Agilent Seahorse XFp Cell Mito Stress Test measures key 
parameters of mitochondrial function by directly measuring the oxygen consumption rate (OCR) 
of live cells. Seahorse XFp Analyzer measures OCR in real-time of the 3 replicates through 
injections of Oligomycin, FCCP, Rotenone, and Antimycin. After the plates were measured, 
cells in each well were sonicated. The data from the 3 replicates were normalized with the DNA 
concentration in each well, measured by NanoDrop™ 2000/2000c Spectrophotometers. 
  
   
 
9 
 
Results 
 
Cell morphology of high and low HA producing Hs578T subclones 
Representative phase contrast images of HAHigh and HALow cultures are shown in Figure 
2A. A clear distinction in cell morphology was observed, with HAHigh cells demonstrating 
fibroblastic features (spindle shaped) and HALow cells exhibiting epithelial morphology 
(cuboidal). At high density, the HALow cells grew as flat monolayers and were larger than the 
HAHigh cells. Thus, sorting Hs578T cells for HA production separated the two morphological 
types of cells which were evident in the parental strain.  
The differences in morphology and HA production in the two cell lines were verified 
with immunofluorescence and particle exclusion assays. Confocal imaging with bHABP showed 
more intense surface HA staining in the HAHigh population than the HALow population (Figure 
2B, Left). To specifically visualize the pericellular matrix, or cell coat, which is mostly 
comprised of cell surface HA anchored via HA synthases and HA-binding proteins (Tamada et 
al., 2012), we conducted particle exclusion assays. This technique utilizes sedimenting fixed 
erythrocytes (which are inherently fluorescent) to outline the edges of the pericellular matrix. 
Consistent with confocal imaging demonstrating extensive cell surface bHABP in the HAHigh 
population, these cells had a more extensive pericellular coat than the HALow population (Figure 
2B, Right). Phase contrast imaging of the low-density cultures used for the particle exclusion 
assay highlighted the smaller overall size and pronounced surface protrusions of the HAHigh cells 
compared to the HALow cells. 
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A. 
 
 
 
 
 
 
B. 
 
 
Effects of DON on Hs578T subclones growth 
Crystal violet assays were used to assess the dose dependent effect of DON on Hs578T 
HAHigh and HALow subclones. Absorbance at 590nm in each well was recorded on a Victor 
microplate reader. The values for each treatment group were compared to that of the control 
wells and expressed as the percentage of the average absorbance (mean ± standard deviation). 
Figure 2. Morphology and HA expression of Hs578T subclones. A. Phase images of HAHigh and HALow subclones. B. 
Right: Confocal imaging of fluorescently labeled bHABP binding to cell-associated HA on Hs578T subclones. Left: Phase 
images and visualization of pericellular HA coat by exclusion of sedimenting fixed erythrocytes on Hs578T subclones. 
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For HALow cells, the average absorbance at each DON dose 98.0±8.4% at 0.5 µM, 83.2 ± 4.6% at  
1 µM and 61.7 ± 1.2%. at 2.5 µM. For HAHigh cells, the average absorbance at each DON dose 
was 95.9±5.9% at 0.5 µM, 87.4 ± 3.0% at 1 µM and, 71.3 ± 1.4%. at 2.5 µM. 
   
 
 
 
 
 
Effects of DON on HA production of the subclones 
 Flow cytometry was performed to characterize the effects of DON on HA production of 
the subclones (Figure 4). For this experiment, a higher dose of DON (10 μM) was utilized at a 
shorter time point (48 hour). DON reduced cell-associated HA on HAHigh cells (16.1% decrease 
of HABP (+) at 10 μM DON). This decrease in the expression of cell-associated HA was not 
observed in the HALow subpopulation treated with DON.  
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Figure 3. Percent Response for 0 µM, 0.5 µM, 1 µM, 2.5 µM DON treatments for 72h. Cells were plated on 24-
well dishes at 7,000 cells/ml density and treated with for 0 µM, 0.5 µM, 1 µM, 2.5 µM DON for 72 hours, stained 
with crystal violet. Absorbance at 590nm was measured using Victor microplate reader. Data represent the 
percentage of the absorbance assessed by Victor microplate reader in each DON treatment with the control (0 nM). 
Mean ± SD of three replicates and are representative of at least three independent experiments. 
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Figure 4. Flow cytometry data of bHABP binding to cell-associated HA on subpopulations incubated with 5 and 10 μM DON 
for 48 hours. The subclones were incubated in respective treatments, trypsinized and pooled. The pooled cells were blocked, 
incubated with biotinylated HA binding protein, and fluorescently labeled. Flow cytometry was performed using BD LSR II 
Flow Cytometer and analyzed using FlowJo 7.6.5. 
 
Effects of DON on glycolytic function in Hs578T subclones  
We also performed Glycolysis Stress Tests of Hs578T subclones pretreated 24h with 5 
μM DON. The Glycolysis Stress Test measures key parameters of glycolytic function (Figure 
5A) by directly measuring the extracellular acidification rate (ECAR) of live cells before and 
after serial injections of glucose, oligomycin (ATP synthase inhibitor) and 2-deoxy-glucose (2-
DG, a glucose analog that inhibits glycolysis through competitive binding to  hexokinase). 
Glycolysis Stress Tests were conducted with Hs578T subclones after treatment with 5 
μM DON for 24 hours. In Figure 5B, ECAR profiles showed significant decreases in both 
glycolytic rate and glycolytic capacity of HAHigh and HALow cells after 5 μM DON treatment. In 
HALow cells, glycolysis rate after glucose addition for untreated cells was 17.96, while that of 
DON treated cells was 10.34. The glycolytic capacity of untreated HALow cells was 24.43, while 
that of DON treated cells was 17.20. In HAHigh cells, the glycolytic rate after glucose addition for 
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untreated cells was 12.98, while that of treated cells was 5.43; the glycolytic capacity of 
untreated cells was 19.31, while the treated was 11.23. For glycolytic reserve, there was a slight 
increase for HALow cells treated with 5 μM DON for 24 hours, while there was a slight decrease 
for HAHigh cells, relative to untreated control cells. 
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A. 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
Figure 5. Effect DON on glycolytic function in live cells. HAHigh cells were plated in Agilent Seahorse XFp cell culture 
microplates. The XFp flux analyzer measured temporal changes in extracellular acidification rate (ECAR) of live cells as 
described in Materials and Methods. A. Glycolysis Stress Test ECAR profile. B. ECAR of Hs578T subclones when treated with 
5 μM DON for 24 hours. Data represents time course of ECAR before and after serial injections of of glucose, oligomycin, 2-
deoxy-glucose (2-DG) and calculated parameters of glycolytic function: glycolysis, glycolytic capacity, glycolytic reserve.  Data 
represent Mean ± SD of at least three independent biological replicates. 
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Effects of DON on mitochondrial respiration in Hs578T HAHigh cells  
We conducted real time metabolic flux assays on the Agilent Seahorse XFp to evaluate if 
HAHigh cells exhibited altered metabolism after DON treatment. The Mito Stress Test measures 
key parameters of mitochondrial function (Figure 6A) by directly measuring the oxygen 
consumption rate (OCR) of live cells before and after serial injections of oligomycin (ATP 
synthase inhibitor), FCCP (uncoupler of oxygen consumption and ATP production), and a mix of 
rotenone and antimycin A (inhibitors of complex I and III, respectively). 
Mito Stress Tests were conducted with HAHigh cells in the presence 5 μM DON for 24 
hours. As shown in Figure 6B, OCR profiles were similar in treated and untreated HAHigh cells, 
with basal and maximal OCR of approximately 20 and 30 respectively.  However, DON treated 
HAHigh cells exhibited a slight increase in ATP production. In addition, spare capacity was 
slightly reduced in HAHigh cells after DON treatment. 
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A. 
 
 
 
 
 
B. 
 
 
Figure 6. Effect DON on mitochondrial respiration HAHigh cells. HAHigh cells were plated in Agilent Seahorse XFp cell culture 
microplates.  The XFp flux analyzer measured temporal changes in oxygen consumption rate (OCR) of live cells as described in 
Materials and Methods. A. Cell Mito Stress Test OCR profile. B. OCR of HAHigh cells when treated with 5 μM DON for 24 
hours. Top: Data represents time course of OCR before and after serial injections of oligomycin, FCCP and rotenone/antimycin 
and calculated parameters of mitochondrial respiration: basal respiration, maximal respiration, ATP production, proton leak, 
and % spare capacity.  Data represent Mean ± SD of at least three independent biological replicates. 
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Discussion 
We examined the HAHigh and HALow subpopulations from basal-like TNBC Hs578T cells 
and found that HAHigh cells exhibit a more aggressive phenotype with increased proliferation, 
enhanced HA secretion and extensive pericellular HA coat. The glutamine analog DON 
significantly reduced growth of both subclones at concentrations of 1.0 μM and above. 
Concentrations of DON of 5-10 µM were used at shorter time points for additional experiments 
on HA production and metabolism. At these concentrations, DON reduced cell-associated HA 
(as measured by flow cytometry of bHABP) in a dose dependent manner in HAHigh cells but had 
no effect on HALow cells. We also examined the effect of DON on glycolysis and respiration of 
live cells in real time using the Seahorse metabolic analyzer.  Our data demonstrated that DON 
inhibited glycolysis (measured as ECAR) of both clones, but HAHigh cells were more sensitive 
than HALow cells.  In contrast, DON did not alter mitochondrial respiration, measured as OCR, in 
HAHigh cells. Thus, the effect of DON on Hs578T cell growth likely reflects its ability to block 
glycolysis rather than mitochondrial respiration. Further studies are warranted to determine the 
link between HA and glycolysis in this model system. 
This project supports the concept of targeting HA synthesis as a therapeutic approach, 
since HA and its degradative enzymes play a central role in promoting tumorigenesis and 
progression of disease (Lokeshwa et al., 2014; Seufferlein et al., 2018; Yahya et al., 2014). 
DON, as a glutamine antagonist, targets GFAT, the key regulator in HBP and reduces HA 
production. In addition, DON blocks glutamine utilization for other cellular needs such as DNA 
synthesis. Evidence suggests that, in general, basal-like TNBC cells are more glutamine 
dependent than other breast cancer subtypes and thus insufficient endogenous glutamine 
synthesis blocks their survival (Kim et al., 2013; Oliveira et al., 2013). In our study, we observed 
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that cells that produce more HA (HAHigh cells) exhibited the more aggressive phenotype and 
were more sensitive to DON treatment with respect to inhibition of growth and glycolysis. 
The therapeutic potential of DON, however, may be impeded by its dose-limiting 
toxicity, specifically gastrointestinal related (Earhart et al., 1990; Magill et al., 1957; Rahman et 
al., 1985). Despite the potential side effects, the promising effects of DON on glutamine 
dependent tumors support the development of strategies to utilize it clinically for TNBC while 
minimizing its toxicity to normal tissues.  
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Conclusion 
This project examined the effects of the glutamine analog DON on growth and   
metabolism of Triple Negative Breast Cancer cells in the context of HA synthesis. We examined 
the morphology of HAHigh and HALow subpopulations and showed that the high HA producing 
subclone (HAHigh) displayed a more aggressive phenotype with an extensive pericellular HA 
coat. Treatment with DON significantly reduced cell growth of both subclones but selectively 
decreased surface HA only in HAHigh cells. Real time metabolism assays showed that treatment 
with 5 μM DON for 24 hours significantly altered glycolysis but not mitochondrial respiration. 
Furthermore, we found that glycolytic metabolism of the HAHigh cells was more sensitive to 
DON treatment than the HALow cells. These findings support the concept that high HA synthesis 
in TNBC may increase glutamine dependency. Thus, glutamine antagonists such as DON may 
provide a new approach to slow TNBC growth through inhibition of HA synthesis.  
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